JNJ 54416076

Drug Profile

JNJ 54416076

Alternative Names: JNJ-54416076

Latest Information Update: 05 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Janssen Research & Development
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Unspecified

Most Recent Events

  • 31 Oct 2016 Janssen Research & Development plans a phase I exploratory trial in Healthy volunteers in USA (PO, Tablet and Suspension) (NCT02951845)
  • 01 Sep 2016 Janssen Research & Development completes a first-in-human phase I trial in Healthy volunteers in Germany (PO) (NCT02670395)
  • 01 Apr 2016 Phase-I clinical trials in Undefined indication (In volunteers) in Germany (PO, Suspension) (NCT02670395)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top